The latest long-term forecast predicts that the AbbVie (NYSE: ABBV) stock price will reach $228 by the end of 2024 and then rise to $276 by the end of 2025. The stock price is expected to continue its upward trend, reaching $331 in 2026, $395 in 2027, $443 in 2028, $492 in 2029, $544 in 2030, $747 in 2035, $984 in 2040, and $1436 in 2050. Based on this forecast, it is safe to say that AbbVie stock prices will experience steady growth in the coming years.
Overview of AbbVie
AbbVie Inc. is a leading biopharmaceutical company focused on developing and delivering advanced therapies for complex diseases. With a global presence in over 175 countries, AbbVie’s portfolio includes leading treatments for immunology, oncology, neuroscience, and aesthetics, driven by its focus on innovation and research.
Key products like Humira, Rinvoq, and Skyrizi anchor its immunology franchise, while drugs such as Imbruvica and Venclexta strengthen its oncology pipeline. AbbVie’s acquisition of Allergan in 2020 also brought Botox and a broader portfolio in neuroscience and aesthetics into its fold.
| Company Name | AbbVie Inc. |
| Country | United States |
| Founded | 2013 (spin-off from Abbott Laboratories) |
| Industry | Pharmaceuticals |
| Sector | Healthcare |
| Ticker Symbol | ABBV (NYSE) |
| CEO | Richard A. Gonzalez |
| Employees | ~50,000 |
| Headquarters | North Chicago, Illinois |
| Products | Specialized in therapeutic areas including immunology, oncology, virology, and neuroscience; key products include Humira, Rinvoq, Skyrizi. |
| Revenue (2023) | $54.32 billion (Pharmaceutical products) |
| Geographic Revenue | United States (77.1%), Other countries (22.9%) |
| Market Cap (2024) | $277.35 billion (May 2024) |
| Top Shareholders | Vanguard Group, BlackRock, State Street Corporation |
| Website | www.abbvie.com |
Long-Term AbbVie Stock Price Predictions
AbbVie Stock Forecasts for 2024, 2025, 2026, 2027, 2030, 2040, and 2050 are available here. TradingView charts and technical analysis are used to forecast or predict the price of AbbVie stock. This price prediction was aided by expert advice and information from other sources.
| Year | Mid-Year | Year-End | Change,% |
| 2024 | $181 | $228 | +17.84% |
| 2025 | $265 | $276 | +42.65% |
| 2026 | $312 | $331 | +71.08% |
| 2027 | $368 | $395 | +104.16% |
| 2028 | $417 | $443 | +128.97% |
| 2029 | $472 | $492 | +154.3% |
| 2030 | $522 | $544 | +181.18% |
| 2035 | $720 | $747 | +286.10% |
| 2040 | $962 | $984 | +408.6% |
| 2050 | $1407 | $1436 | +642.23% |
AbbVie Stock Price History
AbbVie Stock Forecast 2024
AbbVie starting price in 2024 was $143.41. As of today, It was trading at $193.47, indicating a 34.90% increase in price since the beginning of the year. The predicted AbbVie price at the end of 2024 is $231, with a year-on-year growth rate of 61.07%. The increase in price from today to year-end is estimated to be 17.84%, and by mid-2024, we expect to see the price at $181.
AbbVie Stock Price Prediction 2025
According to market projections, AbbVie stock price will reach $265 in the first half of 2025. Furthermore, by the end of the year, it is expected to increase by $11, closing at $276, signifying a remarkable 42.65% increase from the current price.
AbbVie Stock Forecast 2026
Based on a financial forecast, AbbVie stock price is projected to commence at $276 in 2026, followed by a significant elevation to $312 within the first six months of the year, and conclude the year at $331, indicating an overall increase of 71.08% from the present stock price.
More Forecast:
- AMD Stock Forecast
- Bank of America Stock Forecast
- Lucid (LCID) Stock Forecast
- 3M (MMM) Stock Forecast
- Rivian (RIVN) Stock Forecast
AbbVie Stock Price Prediction 2027
According to the latest projections, AbbVie stock value is expected to increase significantly in the coming years. By 2027, the stock is predicted to start at $331, then experience a notable boost within the first six months of the year, soaring to $368. The upward trend is expected to continue, with the stock finishing the year at $395, representing a substantial 104.16% increase from its current value.
AbbVie Stock Price Forecast 2028
According to our analysis, AbbVie is expected to start the year 2028 at a value of $395 and rise to $417 within the first six months of the year. By the end of 2028, it is predicted to reach $443, implying a growth rate of approximately 128.97% from its current value.
AbbVie Stock Forecast 2029
According to market analysts, AbbVie stock is predicted to experience significant growth over the next few years. It is estimated that by the start of 2029, the stock will be valued at $443. Over the first six months of the year, it is expected to soar to $472, reflecting a substantial increase in value. By the end of 2029, AbbVie stock is forecasted to reach $492, indicating an impressive 154.3% increase from its current value.
AbbVie Stock Price Prediction 2030
According to the latest projections, it is believed that AbbVie stock price will start the year 2030 at $492. This is expected to be followed by a steady climb, with the stock reaching $522 within the first half of the year. The trend is expected to continue, and AbbVie stock is predicted to finish the year at $544. This represents a significant increase of about +181.18% from the current stock price, making it an attractive investment opportunity for those looking to invest in the company.
AbbVie Stock Price Prediction 2035
Based on a long-term analysis of AbbVie stock, it is predicted that the value of AbbVie shares will rise significantly by the year 2035. Specifically, the price of AbbVie is expected to increase to $747, representing a gain of +286.10%. This prediction takes into account various market factors and trends that are expected to impact the performance of AbbVie over the next two decades.
AbbVie Stock Forecast 2040
According to a long-term forecast analysis, the price of AbbVie stock will significantly increase to $984 by 2040, representing a gain of over 408.6%. This positive trend is expected to continue in the years to come, resulting in a profitable opportunity for investors.
AbbVie Stock Price Prediction 2050
Based on an analysis of the S&P 500 as the benchmark, it is predicted that the value of AbbVie stock will soar to $1436, representing an exceptional increase of +642.23% by the year 2050. This forecast indicates a highly promising outlook for AbbVie future growth and profitability and suggests that the company is well-positioned to continue its impressive performance in the long term.
Is AbbVie overvalued or undervalued?
AbbVie is currently overvalued. The intrinsic value of one AbbVie stock is estimated to be 161.582 USD under the Base Case scenario, while the current market price is 193.47 USD, making it overvalued by 20%.
Is AbbVie a Good Long-Term Buy?
Yes, AbbVie is a good long-term buy. Despite losing Humira’s patent protection, the company has effectively transitioned by growing newer drugs like Skyrizi and Rinvoq, which are expected to generate significant revenue in the coming years. AbbVie’s strategic acquisitions, such as Allergan and Cerevel Therapeutics, have diversified its portfolio, reducing reliance on a single blockbuster drug.
With projected earnings growth of 8% to 10% annually through 2027, and a current dividend yield of 3.5%, AbbVie offers both growth and income potential. Although the stock has risen 30% recently, its valuation remains fair, making it an attractive option for long-term investors looking for a solid blue-chip pharmaceutical stock.
FAQs
AbbVie currently holds a Buy consensus rating. This rating is based on the evaluation of 16 strong buy ratings, 5 buy ratings, 9 hold ratings, 0 sell ratings, and 0 strong sell ratings.
AbbVie stock price is expected to increase by 154.3%, from $193.47 to $492, within the next five years.
AbbVie stock price is expected to increase by 286.10%, from $193.47 to $747, within the next ten years.
Based on the current analysis, AbbVie stock would need to gain an extraordinary 158.38% to reach $500. According to the forecast, AbbVie stock will reach $500 by 2030.
Based on the current analysis, AbbVie stock would need to gain an extraordinary 418.77% to reach $1000. According to the forecast, AbbVie stock will not reach $1000 by 2050.
Based on the current analysis, AbbVie stock would need to gain an extraordinary 933.54% to reach $2,000. According to the forecast, AbbVie stock will not reach $2,000 by 2050.
DISCLAIMER: The following information is intended for general knowledge purposes only. None of the information, materials, services, or other content provided on this page should be considered as solicitation, recommendation, endorsement, or financial, investment, or any other type of advice. Prior to making any investment decisions, it is advised to seek independent professional consultation in the form of legal, financial, and fiscal advice.
